WallStreetZenWallStreetZen

NASDAQ: XFOR
X4 Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
X4 Pharmaceuticals earnings were -$90.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest XFOR earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$16.2M, down 20.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, XFOR reported annual earnings of -$79.2M, with 111.5% growth. The next XFOR earnings date is Nov 4, 2026.

XFOR past earnings growth

How has XFOR's earnings growth performed historically?

Company
N/A
Industry
18.13%
Market
90.94%
XFOR's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
XFOR's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

XFOR earnings history

Current Revenue
$15.8M
Current Earnings
-$90.1M
Current Profit Margin
-568.8%

XFOR Return on Equity

Current Company
-63.1%
Current Industry
-10.8%
Current Market
30.9%
XFOR's Return on Equity (-63.1%)... subscribe to Premium to read more.
High Return on Equity Performance

XFOR Return on Assets

Current Company
-36.9%
Current Industry
-10.7%
XFOR is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when XFOR announces earnings.

XFOR Return on Capital Employed

Current Company
-34.84%
Current Industry
-7.4%
XFOR has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

XFOR vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
XFOR-$77.77M-$90.14M-91.62%$0.02
RCKT$2.97M-$17.25MN/A-$0.16
BBOT-$181.36M-$182.11MN/A-$1,230.15
FATE-$114.01M-$126.00MN/A-$1.05
FULC-$83.75M-$85.00MN/A-$1.21
View Top Biotech Stocks

XFOR earnings dates

Next earnings date
Nov 4, 2026

X4 Pharmaceuticals Earnings Reports & History FAQ

What were X4 Pharmaceuticals's earnings last quarter?

On XFOR's earnings call on Aug 14, 2026, X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 2026 earnings per share (EPS) of -$0.13, up 96.25% year over year. Total XFOR earnings for the quarter were -$16.16 million. In the same quarter last year, X4 Pharmaceuticals's earnings per share (EPS) was -$3.47.

If you're new to stock investing, here's how to buy X4 Pharmaceuticals stock.

When does X4 Pharmaceuticals report earnings?

The next XFOR earnings call is Nov 4, 2026. Add XFOR to your watchlist to be reminded of X4 Pharmaceuticals's next earnings date.

Is X4 Pharmaceuticals profitable or losing money?

As of the last X4 Pharmaceuticals earnings report, X4 Pharmaceuticals is currently losing money. X4 Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$90.14 million, a 11.61% decrease year over year.

What was XFOR's earnings growth in the past year?

As of X4 Pharmaceuticals's earnings date in Aug 14, 2026, X4 Pharmaceuticals's earnings has grown year over year. XFOR earnings in the past year totalled -$90.14 million.

What are X4 Pharmaceuticals's earnings expectations?

The current EPS estimate for X4 Pharmaceuticals's earnings report in Nov 4, 2026 is -$0.19.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.